Trial Profile
Neoadjuvant and Adjuvant Durvalumab in Combination With Neoadjuvant Chemotherapy in Patients With Operable Urothelial Cancer. A Multicenter, Single-arm Phase II Trial
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 21 Aug 2023
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Cisplatin; Gemcitabine
- Indications Bladder cancer; Urethral cancer; Urogenital cancer
- Focus Therapeutic Use
- 17 Aug 2023 Results of primary analysis published in the Journal of Clinical Oncology
- 07 Jun 2022 Primary endpoint (Event-free survival (EFS)) has been met as per results presented at the 58th Annual Meeting of the American Society of Clinical Oncology
- 07 Jun 2022 Results presented at the 58th Annual Meeting of the American Society of Clinical Oncology